Recently, two PSMA-targeted radiopharmaceuticals for PET imaging of PCa received FDA approval: [68Ga]Ga-PSMA-11 in December 2020 [17] and [18F]DCFPyL in May 2021 [18]. This evidence concerns the gene FOLH1 and posterior cortical atrophy.